Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
RB001
The First People's Hospital of Lianyungang
Phelan-McDermid Syndrome
1 trial -
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Hospital Authority, Hong Kong
Hemodynamic Instability
1 trial -
RNL-Vascostem®
Cellectar Biosciences
Buerger's Disease
1 trial -
RT-PCR Test
BRIGHT MINDS BIOSCIENCES INC.
COVID-19
1 trial -
Rabeprazole
Universal Integrated
Peptic Ulcer Disease
1 trial -
Rabeprazole 20mg twice daily
Hospital Authority, Hong Kong
Chest Pain
1 trial -
Radiation
Adaptive Biotechnologies Corp
Rectal Cancer
1 trial -
Radiation therapy
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Radiotherapy combined with TKI and Anti-PD-1 Antibody
Jian Li
Stage IIIA Hepatocellular Carcinoma
1 trial -
Recombinant COVID-19 Vaccine (Sf9 Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
Redefine
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Obesity & Overweight
1 trial -
Reduced Nicotine Content Cigarettes
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Dependence
2 trials -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Rehabilitation Therapy as part of Standard of Care (Control)
BRIGHT MINDS BIOSCIENCES INC.
Acute Stroke
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Bacterial Overgrowth Syndrome Small Bowel
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenic Purpura
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
Romiplostim N01
The First People's Hospital of Lianyungang
Primacy Immune Thrombocytopenia
1 trial -
Rozerem
Takeda
REM Behavior Disorder
1 trial -
Ruxolitinib+Calcineurin inhibitor+Methotrexate
The First People's Hospital of Lianyungang
Graft Versus Host Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources